Newsfile Corp
16 Aug 2026, 01:31 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Regeneron's Phase III Fianlimab-Libtayo trial failed to reach statistical significance for its primary endpoint of improvement in progression-free survival. — The failure of a Phase III clinical trial for a key drug candidate is a major fundamental blow to a biotech company's growth pipeline and valuation.
-0.80A securities class action lawsuit alleges that Regeneron executives made false or misleading statements regarding the Fianlimab-Libtayo study's flawed statistical assumptions. — Legal challenges and allegations of fraud create corporate governance risks and potential for significant financial settlements.
-0.40Regeneron altered the Phase III study on April 29, 2026, to expand the number of patients eligible for analysis of progression-free survival. — Mid-study protocol changes are often viewed by investors as a sign of struggle to meet original endpoints.
-0.20Which stocks this story touches
Continue reading
6 related stories
Search tags
The company is facing a securities class action lawsuit following the failure of a Phase III clinical trial and allegations of misleading investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
51m ago
